Research is a critical part of the development of new medicines, but it doesn’t stop once the medicine is approved by the U.S. Food and Drug Administration (FDA).  In fact, that’s when post-approval research and monitoring begin and they help all health care stakeholders, including physicians and patients, to better understand the full value of… Read More

No matter if clinical trials are sponsored by the industry or government, they have the goal to improve or discover completely new ways for treating diseases. But most of all, researches are capable of dictating the advancement of medicine and healthcare. There are millions of volunteers who realize how important for the sector and humans… Read More

Eli Lilly and Company LLY announced encouraging results from two phase III studies, UNCOVER-2 and UNCOVER-3, on ixekizumab for the treatment of patients with moderate-to-severe plaque psoriasis. This double-blind, multicenter, phase III studies evaluated ixekizumab, in comparison to Amgen Inc.’s AMGN Enbrel (etanercept) or placebo, in patients with moderate-to-severe plaque psoriasis. In both the studies,… Read More

Allergic contact dermatitis is often missed in pediatric patients who present with eczema-like skin eruptions, in part because less is known about ACD in children than in adults. “Often when we see a child with dermatitis, we automatically think of atopic dermatitis, but we should also consider the possibility of allergic contact dermatitis,” Dr. Joseph… Read More

We have opened up a new office in New Albany, Indiana . Our Location is at 2241 Green Valley Road, New Albany, IN 47150 . Below we have pictures of our new office and staff.  We have also partnered with another local dermatology specialist  “Associates in Dermatology ” for the purpose of studying  psoriasis, acne, and rosacea.

A US subsidiary of Dr Reddy’s laboratory, Promius Pharma, has been successful in getting US FDA approval for its psoriasis spray. This prescription spray, called Sernivo, contains 0.05% betamethasone dipropionate and can be used for external application for psoriasis among patients who are 18 years or over. “As an emerging leader in the dermatology space,… Read More

By Zacks Equity Research  AG NVS announced that the FDA has approved its arthritis drug, Cosentyx (secukinumab), in two new indications – for the treatment of adults with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA). The approvals came on the back of positive efficacy and safety outcomes from four placebo-controlled phase III studies.… Read More

PALO ALTO, Calif.–(BUSINESS WIRE)–Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of crisaborole topical ointment, 2%, a novel non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis in children and adults.… Read More

Our skin is the largest organ of our body, making skincare a multi-billion dollar industry.  Shelves are stocked full of products for the treatment and papering of our skin.  Creams and oils claiming to turn back the clock and remove wrinkles, ointments for warts, Eczema, or other conditions, and more lotions than you can imagine… Read More